Karen Huelsman, MS, LGCPrecision Oncology Lead and Licensed Genetic Counselor, TriHealth Precision Medicine and TriHealth Cancer Institute
live WEBINAR
Closing gaps in early-stage NSCLC with AI-enabled clinical intelligence
A deep dive into the ASCO 2026 Landmark study on improving biomarker testing and guideline-concordant care
Wednesday, October 14, 2026
9 AM PT / 11 AM CT / 12 PM ET
REGISTER NOW
All registrants will be sent the webinar recording shortly following the completion of the session.
what you’ll learn
For patients with early-stage non-small cell lung cancer (eNSCLC), timely and complete biomarker testing is critical for perioperative planning and access to targeted therapies. However, keeping pace with evolving guidelines and identifying eligible patients from complex, unstructured EHR data presents a significant challenge for health systems, often leading to care gaps. How can technology help bridge the gap between clinical guidelines and real-world practice?
Join us for a discussion on the findings of a multi-center, prospective study presented at the ASCO 2026 Annual Meeting. The study evaluated an AI-enabled clinical decision support program deployed across six geographically and socioeconomically diverse US community health systems, resulting in an absolute lift of up to +24% in biomarker testing rates. We will explore the study’s methodology, which combined education, real-time EHR monitoring and alerts, and longitudinal feedback dashboards to address non-adherence to biomarker testing guidelines. Panelists will discuss the study’s results and the real-world implications for clinicians, patients, and the future of AI in helping clinicians ensure patients receive guideline-concordant care.
This session will cover:
- The clinical challenges and importance of timely biomarker testing for patients with early-stage NSCLC.
- Key results from a multi-center study, in which implementation of an AI-enabled program was associated with an absolute lift of up to +24% in biomarker testing rates.
- Perspectives from clinical investigators on how an AI-powered program can be integrated into existing workflows to support guideline-concordant care.
SPEAKERS
READ BIO
Karen Huelsman oversees Precision Oncology at TriHealth with 24 years of experience in oncology genomics. She guides testing for over 55 oncology providers, leads the Molecular Tumor Board, advances EMR‑integrated genomic workflows, and drives QI projects. She is a national speaker and published author in somatic and germline cancer genomics.
Dr. George SimonVice President of Oncology, OhioHealth
READ BIO
Dr. Simon currently serves as Vice President, Oncology for the OhioHealth Network, where he oversees Oncology strategy, operations and research for the enterprise. Most recently, Dr. Simon served as tenured Professor and Executive Medical Director/Dept. Chair at the H Lee Moffitt Cancer Center in Tampa, FL, prior to which he served as Professor of Medicine and Section Chief, Translational Research, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX Dr. Simon’s research interests include individualizing therapy based on precision therapeutic strategies, and early drug development. Some of his research has been funded by the National Cancer Institute (R21, R01, Lung Cancer SPORE) and Department of Defense grants. He also holds two US patents.
Heather RudicilExecutive Director of Personalized Medicine, Community Health Network (CHN)
READ BIO
Heather is an accomplished healthcare leader with more than two decades of experience driving innovation, transformation, and personalized medicine within a complex health system. As Executive Director of Personalized Medicine, she brings deep operational expertise in integrating emerging technologies and AI enabled clinical intelligence into real-world clinical workflows. Heather offers a practical health-system perspective on closing gaps in care, optimizing workflows and improving outcomes for patients while also creating the ‘easy button’ to support clinical decision making and alleviating provider burden and burnout.
Dr. Ezra CohenChief Medical Officer of Oncology, Tempus
READ BIO
Dr. Cohen is a leading medical oncologist and cancer researcher who brings a unique combination of extensive clinical and research experience to Tempus’ leadership team. He was most recently the Chief of the Division of Hematology-Oncology as well as the Associate Director of Clinical Science at UC San Diego (UCSD) Moores Cancer Center. Dr. Cohen also led the Precision Immunotherapy Clinic and co-directed the San Diego Center for Precision Immunotherapy at UCSD. Before UCSD, Dr. Cohen spent 15 years at the University of Chicago, where he was the co-director of the Head and Neck Cancer Program as well as Hematology/Oncology Fellowship Program Director.
